Regina Schwind

VP Clinical Data @triomics Cancer sucks... support research for cures!! Opinions shared are my own

[Mount Sinai Tisch Cancer Center @TischCancer]

Therica Miller @IcahnMountSinai is co-author on this paper in @npjDigitalMed:
PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models
https://t.co/t2fZ89212u

[Regina Schwind @gg_schwind]

🙌🏼 so proud of our team for this novel and impactful work!

[npj Digital Medicine @npjDigitalMed]

Matching patients to #ClinicalTrials is usually complex and time-consuming, often leaving patients unaware of potential treatment options.

This study presents a custom fine-tuned language model that uses real-world patient data to automate trial matching, showing performance equal to qualified doctors and better than GPT-3.5 in identifying eligible patients.

https://t.co/3xSBL2Nqyh

[Michael Schwartz @MSchwartzTV]

Just another day of Buffalo being soft

[Sabeen Dhand @SDhandMD]

Not only do these socks provide great compression, but they are amazing to use to explain the intervention to patients pre and post procedure!! They … and I love it. Thx @JillSommerset

@drcostantino1 @kmadass @LessneVIR @keithppereira @FadiSaab17 @jmills1955 @AmputationSuck

[Tempus @TempusAI]

We're excited to announce our new ctDNA assay, xF Monitor, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients w/ advanced cancers. Now available for research use only. Learn more: https://t.co/LiuFAYF6E1

[Elizabeth Plimack MD @ERPlimackMD]

Applause mid-presentation marking the moment the standard of care changed in #bladdercancer The data speaks for itself, but @tompowles1 spoke for all of us thanking patients, not just those on EV 302, but the many who came before allowing us to celebrate this milestone #EVPembro

[David Cohn, MD, MBA @David_Cohn_MD]

Another wonderful installment of the Heather Pick music program at @OSUCCC_James

The beautiful voice, guitar and harmonica provided by Dennis Smith (following a 21-year career at the James, including as COO) left our patients, families and staff with a feeling of #Hope

[David Cohn, MD, MBA @David_Cohn_MD]

It’s always great to spread the word about the wonderful work underway at the @OSUCCC_James—and there’s no better way to do that than surrounded by tens-of-thousands at #TheShoe. Thanks to all who took place in this great event last week.

[Amanda Haddock 🧬 @AmandaHaddock]

13 years ago this month, my son was diagnosed with brain cancer. I promised him that I would do everything I could to help kids with #ChildhoodCancer. It’s the only thing he asked us to do. Not to help him, but to help others. I would be grateful for a follow or a RT to spread awareness and honor his journey. 🙏🏻

[Irum Khan @Irumkhan_hem]

Exciting collab w DrTyner ⁦@OHSUKnight⁩ and ⁦⁩ ⁦@UICancerCenter⁩ leveraging BeatAML data to show FOXM1 underlies chemosensitivty in NPM1mut AML and investigating a novel FOXM1 inhibitor ⁦@ACS_Research⁩ ⁦⁦⁦@LurieCancer⁩ https://t.co/TIsPzbXPNg

[Tempus @TempusAI]

Learn the value of RNA sequencing in identifying altered expression programs in tumors that are measurable by RNA-Seq, but not DNA-Seq, in a recent article by Josh SK Bell. Read here: https://t.co/arVBoI21hz

[Tempus @TempusAI]

#NEWS: We're thrilled to announce that the FDA has approved our first Premarket Approval (PMA) application for our companion diagnostic test, xT CDx. xT CDx is a 648-gene next-gen sequencing test for solid tumor profiling in colorectal cancer patients: https://t.co/eKhWJFo5EQ

[Buffalo Bills @BuffaloBills]

Damar Hamlin FaceTimed into our team meeting today to talk to players and coaches.

What he said to the team: “Love you boys.” ❤️

[Tempus @TempusAI]

#NEWS: We’re excited to announce a new study w/ @AstraZeneca that aims to identify biomarkers of response in patients w/ #SCLC, an aggressive disease in which there is a high unmet need for therapeutic targets. The study is open for enrollment. Learn more: https://t.co/k6Nfqux32X

[Tempus @TempusAI]

Meet Allison Karas – Lead Product Designer at Tempus. We’re grateful to have Allison & her team as they work to shape the look, feel and efficiency of our products for our customers. Listen in to hear what accomplishments she is most proud of this year. #TeamTempus

[Electra Paskett @e_paskett]

I am the editor of a new journal launched today. Check POE out! We welcome inquiries and submissions. https://t.co/RxZ1H45fNf

[David Cohn, MD, MBA @David_Cohn_MD]

You don’t need a bike to be a part of @Pelotonia (though I highly recommend it 😁). If you’re still on the fence, check out this rundown of all the ways you can get involved this summer. https://t.co/N2Q8f17DRT

[Tempus @TempusAI]

Tempus is uniquely positioned to contribute this kind of targeted, longitudinal dataset for research. In this study, Lens identified/analyzed a large cohort of patients w/ metastatic #breastcancer that had both solid tumor & liquid #NGS testing over time. https://t.co/XkR7pbzIJy

[Tempus @TempusAI]

Join our COO @RyFukushima and @JanssenGlobal Chief Data Science Officer for R&D, Najat Khan, Ph.D., on 6/14 at 12pm CT for a discussion on how advanced AI algorithms applied to #RWD are helping to achieve major milestones in #oncology R&D. Register here: https://t.co/Z1BOi4UaPc

[Tempus @TempusAI]

New Tempus data from #ASCO22 shows that adding liquid biopsy to tissue-based #NGS matches more patients to therapies across multiple solid tumors compared to tissue testing alone. Learn more: https://t.co/nqbjfm5rjn